Does Lower-Limb Resistance Training Help Diabetic Foot Ulcers?
An RCT finds lower-limb resistance training improves glycaemic control and quality of life in diabetic foot ulcer patients, but not wound healing. PICO summary and commentary.
Metabolism
Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
Prolonged Sleep Restriction Reduces TSH Levels in Healthy Women: Pooled RCT Analysis
Pooled RCTs find mild sleep restriction lowers TSH in women specifically, with no effect overall and no change in FT4. PICO summary and expert commentary.
ESSENCE Trial: Phase 3 Design and Baseline Characteristics of Semaglutide 2.4 mg in MASH
Design and baseline-cohort paper for the phase 3 ESSENCE trial of semaglutide 2.4 mg in biopsy-proven MASH with fibrosis stage 2 or 3; no efficacy outcomes are reported. PICO summary and expert commentary.
Oral Semaglutide and Appetite Control Trial
A small mechanistic randomized trial found once-daily oral semaglutide 50 mg cut ad libitum energy intake by 39.2 percentage points versus placebo and reduced body weight, with no change in gastric emptying. PICO summary and expert commentary.
Semaglutide 2.4 mg in obesity and prediabetes (STEP 10): superior weight loss and reversion to normoglycaemia
STEP 10 phase 3 RCT: once-weekly semaglutide 2.4 mg cut bodyweight by 13.9% and drove reversion to normoglycaemia in adults with obesity and prediabetes. PICO summary and expert commentary.
STEP-HFpEF Pooled Analysis
Pooled subgroup analysis of STEP-HFpEF and STEP-HFpEF-DM finds once-weekly semaglutide 2.4 mg improves symptoms and weight across diuretic strata and cuts loop diuretic dose in obesity-related HFpEF. PICO summary and expert commentary.
STEP-HFpEF: Semaglutide Benefits Consistent Across Baseline Inflammation
A prespecified pooled secondary analysis of the STEP-HFpEF trials found semaglutide improved symptoms, weight, and exercise capacity consistently across baseline C-reactive protein strata and lowered CRP regardless of weight loss. PICO summary and expert commentary.
Integrated Data Platform Plus Dietary Management in Type 2 Diabetes: A Randomized Controlled Trial
A single-centre RCT (n=180) testing an integrated cloud data platform with dietary management and education videos against routine care in type 2 diabetes, with HbA1c lower at 12 weeks. PICO summary and expert commentary.
Very-Low Calorie Diet and Semaglutide in Type 2 Diabetes
A 12-week pilot RCT comparing an 800 kcal/day very-low calorie diet, semaglutide, and their combination in 30 adults with type 2 diabetes. PICO summary and expert commentary.